Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolution of Growth Rate in Children Treated With Growth Hormone
2004-002991-40Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in Growth disorder, sponsored by Pfizer. Primary endpoint: Change in annual growth rate SDS at 36 months.
02
Drugs
somatropin
03
Conditions
Growth disorder
Beyond the preview
Go deeper on 2004-002991-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002991-40.